Nature Reviews Drug Discovery contents July 2012 Volume 11 Number 7 pp 499-579

Advertisement
Knome provides researchers and clinics with human whole genome interpretation software and services. Visit www.knome.com to learn how we can help you identify the variants, genes, and gene sets that underlie disease and drug response.
TABLE OF CONTENTS
July 2012 Volume 11 Number 7
Impact Factor 28.712 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month  Featured article: Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars Steven A. Berkowitz, John R. Engen, Jeffrey R. Mazzeo & Graham B. Jones
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Relay Technology Management Real time business intelligence and data visualization for the Life Science Industry Trend monitoring and comparative asset analysis Click here for more information or to arrange a trial.
In this issue p499 | doi:10.1038/nrd3786 Full Text
Comment: New horizons in pharmaceutical regulation Alasdair Breckenridge, Michelle Mello & Bruce M. Psaty p501 | doi:10.1038/nrd3787 Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Anticancer TLR agonists on the ropes Malini Guha p503 | doi:10.1038/nrd3775 Toll-like receptor agonists have hit another setback with the Phase II failure of Idera's IMO-2055, but these immunotherapies may still make a comeback if appropriate combinations with vaccine antigens or anticancer drugs can be identified. PDF
Drug repurposing programmes get lift off Asher Mullard p505 | doi:10.1038/nrd3776 What will schemes designed to get industry's discarded drug candidates into the hands of academic researchers deliver? PDF
NEWS IN BRIEF Antibiotic R&D gets a dose of funding | FDA on track with first-half approvals | SGLT2, take two? p507 | doi:10.1038/nrd3784 PDF
BIOBUSINESS BRIEFS Deal watch: Epizyme–Celgene deal signals interest in new class of epigenetic drugs Alexandra Flemming p508 | doi:10.1038/nrd3772 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q3 2012 Robert Jeng p508 | doi:10.1038/nrd3773 PDF
BIOBUSINESS BRIEFS Regulatory watch: Crossing the regulatory finish line p509 | doi:10.1038/nrd3774 PDF
PATENT WATCH China aims to enhance IP laws | Two routes to patent challenge can give different results | 23andMe patent creates a stir | Toll-like receptor agonists and cancer Charlotte Harrison p510 | doi:10.1038/nrd3785 PDF
AN AUDIENCE WITH Alan Trounson p512 | doi:10.1038/nrd3769 Alan Trounson, President of the California Institute for Regenerative Medicine, discusses his plans to get more stem cell therapeutics into trials. PDF
FROM THE ANALYST'S COUCH FDA advisory committee meeting outcomes Jeffrey F. Smith, Seth A. Townsend, Navjot Singh & Philip Ma p513 | doi:10.1038/nrd3747 This analysis of the outcomes of advisory committee meetings held by the US Food and Drug Administration (FDA) over the past decade investigates issues such as the consistency between advisory committee votes and FDA approval decisions. PDF
RESEARCH HIGHLIGHTS Top Cancer: Of targets and anti-targets p515 | doi:10.1038/nrd3781 PDF Metabolic disorders: Heart microRNA provides new route to metabolic control p516 | doi:10.1038/nrd3779 PDF Anticancer drugs: Antipsychotic to anticancer agent? p516 | doi:10.1038/nrd3783 PDF Anticancer drugs: Reactivating p53 p517 | doi:10.1038/nrd3782 PDF Neurodevelopmental disorders: Exploring the links between SHANK2 and autism p518 | doi:10.1038/nrd3780 PDF IN BRIEF Ageing: Telomerase gene therapy increases longevity | Cardiovascular disorders: A new class of antithrombotic agents | Neurodegenerative disorders: Alzheimer's toxic chain reaction | Diabetes: A mechanism of metabolically driven pain PDF Drug Discovery JOBS of the week Post-doctoral research position (“Experienced researcher still in his / her early career”) in Molecular modeling of nanoparticles for drug delivery SANOFI R&D Research Associate, Drug Metabolism Pharmacokinetics Otsuka Scientist, Drug Evaluation Otsuka Postdoctoral Scholar – Enzymology and Drug Development Penn State College of Medicine Metabolomics of fungal diseases: a systems biology approach for biomarkers discovery and therapy. Dipartimento di Medicina Sperimentale e Scienze Biochimiche More Science jobs from Drug Discovery EVENT International Conference on Central Nervous System - Drugs Effects & Novel Drug Development 05.-07.09.12 PA, US More science events from
Advertisement
JAX­® In Vivo Pharmacology Services Customizable testing services follow custom or conventional protocols to accelerate your drug discovery research. Learn about our humanized NOD scid gamma mice endowed with a human immune system and our patient-derived xenograft resource - a library of diverse and representative patient-derived tumor xenograft (PDX) models to support basic cancer research, biomarker discovery and drug testing.
PERSPECTIVES		Top
OPINION Antibody-enabled small-molecule drug discovery Alastair D. G. Lawson p519 | doi:10.1038/nrd3756 Here, Lawson proposes that the use of antibodies as tools in small-molecule drug discovery — for example, to validate targets, enable crystallography and to constrain proteins for screening — could reduce risks and facilitate the modulation of traditionally intractable targets, such as protein–protein interactions. Abstract | Full Text | PDF
REVIEWS		Top
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars Steven A. Berkowitz, John R. Engen, Jeffrey R. Mazzeo & Graham B. Jones p527 | doi:10.1038/nrd3746 Biopharmaceuticals are much more complex than small-molecule drugs, which raises challenging questions for the development and regulatory evaluation of follow-on versions (also known as biosimilars). Jones and colleagues discuss the current state of the art in analytical technologies to assess three characteristics of protein biopharmaceuticals that regulatory authorities have identified as being important for biosimilars: post-translational modifications, three-dimensional structures and protein aggregation. Abstract | Full Text | PDF
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma Kang Zhang, Liangfang Zhang & Robert N. Weinreb p541 | doi:10.1038/nrd3745 During the past decade, there have been substantial advances in our understanding of the pathogenesis and genetics of eye diseases. Focusing on glaucoma and retinal disorders, Zhang and colleagues review the current status of ocular drug therapy, discuss novel agents currently in development and clinical trials and highlight recent advances in drug delivery. Abstract | Full Text | PDF
Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap Judith Pratt, Catherine Winchester, Neil Dawson & Brian Morris p560 | doi:10.1038/nrd3649 The paucity of treatments for schizophrenia might be partly due to the lack of suitable animal models in which to assess potential new drugs. Here, the authors highlight how new rodent models that are based on a better understanding of the genetics and neural circuitry underlying schizophrenia could lead to the development of more effective drugs. Abstract | Full Text | PDF
Erratum: Busy panels recommend Pfizer's tofacitinib, Arena's lorcaserin and more Asher Mullard p579 | doi:10.1038/nrd3778 Full Text | PDF
Erratum: Amgen builds secondary hyperparathyroidism pipeline Man Tsuey Tse p579 | doi:10.1038/nrd3791 Full Text | PDF
Advertisement
Scientific Reports publishes 457 open access papers in its first year Publishing technically sound research articles, Scientific Reports is Nature Publishing Group’s fastest growing journal. Given the speed and visibility offered, no wonder 93% of our authors said that they are “likely” or “very likely” to submit again. Keep your research moving. Submit to Scientific Reports
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.